Amicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Leerink Swann
Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reaffirmed by equities research analysts at Leerink Swann in a research report issued on Wednesday. They presently have a $20.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $17.00. Leerink Swann’s price target would suggest a potential upside of 23.15% from the stock’s previous close.
Several other equities research analysts have also recently weighed in on FOLD. BidaskClub cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital increased their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research note on Thursday, August 10th. Bank of America Corporation increased their price target on Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. J P Morgan Chase & Co reissued an “overweight” rating and issued a $15.00 price target (up previously from $13.00) on shares of Amicus Therapeutics in a research note on Wednesday, August 9th. Finally, Cowen and Company reissued a “buy” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research note on Monday, August 14th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Buy” and an average target price of $18.25.
Amicus Therapeutics (NASDAQ:FOLD) traded down 3.57% during trading on Wednesday, hitting $15.66. The stock had a trading volume of 3,280,669 shares. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $16.60. The company’s market cap is $2.58 billion. The company has a 50-day moving average of $13.93 and a 200 day moving average of $10.49.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. On average, equities research analysts anticipate that Amicus Therapeutics will post ($1.32) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Stock Rating Reaffirmed by Leerink Swann” was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/04/amicus-therapeutics-inc-fold-earns-outperform-rating-from-leerink-swann.html.
In other Amicus Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average price of $12.25 per share, with a total value of $18,375,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.40% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. FMR LLC boosted its holdings in Amicus Therapeutics by 3.4% in the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after acquiring an additional 705,153 shares in the last quarter. Redmile Group LLC boosted its holdings in Amicus Therapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after acquiring an additional 668,080 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after acquiring an additional 430,486 shares in the last quarter. Palo Alto Investors LLC boosted its holdings in Amicus Therapeutics by 0.7% in the second quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock worth $79,964,000 after acquiring an additional 57,800 shares in the last quarter. Finally, Janus Capital Management LLC boosted its holdings in Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock worth $50,883,000 after acquiring an additional 244,906 shares in the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.